The patient is referred to haematology. On review you note he has widespread lymphadenopathy, splenomegaly and weight loss. You decide to commence him on treatment.
He has no past medical history and appears fit to undergo chemotherapy.
You have requested cytogenetics analysis, and results have shown 17q deletion in 35% of cells. What does this indicate?
how does this affect you management? What would be your management plan?